Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{210908,
        author = {Ankit Kumar Yadav and Anoop Kumar Singh},
        title = {Quality by Design-Guided Silymarin-Phospholipid Phytosomal Complex for Enhanced Oral Delivery and Hepatoprotection: A Short Review},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {13},
        number = {6},
        pages = {2791-2805},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=210908},
        abstract = {Silymarin, the standardised flavonolignan extract of the fruits and seeds of milk thistle (Silybum marianum), is among the most widely used hepatoprotective phytopharmaceuticals, and its antioxidant, membrane-stabilising, anti-inflammatory and regenerative actions in the liver are well documented. Its oral utility is nevertheless limited by unfavourable biopharmaceutics. Silymarin is a poorly water-soluble, Biopharmaceutics Classification System Class II material whose principal constituent, silybin, undergoes extensive first-pass glucuronidation and sulfation, so that its absolute oral bioavailability is very low and conventional products must be given at a high dose several times a day. Complexation with phospholipid, the technology commonly termed phytosome, addresses this mismatch by converting a polar phenolic into an amphiphilic complex through hydrogen bonding with the head group of phosphatidylcholines, and silybin-phosphatidylcholine complexes are already marketed. Published silymarin phytosome studies, however, have largely relied on one-factor-at-a-time or simple factorial optimisation. This short review examines the case for a silymarin-phospholipid phytosome developed within a Quality by Design framework, using a three-factor Box-Behnken design with the phospholipid-to-drug molar ratio, reaction temperature and reaction time as variables. The hepatic pharmacology and biopharmaceutical limitations of silymarin, the chemistry and preparation of phytosomes, the formulation variables, the precedent in the literature, the optimisation design, the characterisation, dissolution, solid-dosage and stability programme, and a framework for relating in vitro improvement to in vivo exposure and hepatoprotection in a carbon tetrachloride model are discussed in turn. The review concludes that a design-space-optimised silymarin phytosome is a rational, experimentally tractable route to improved oral delivery, and it identifies the scientific and translational challenges that remain.},
        keywords = {Silymarin; silybin; phytosome; phospholipid complex; oral bioavailability; Quality by Design; Box-Behnken design; hepatoprotection; carbon tetrachloride},
        month = {November},
        }